Gerência De Desenvolvimento Clínico - Biosimilar (oncologia) - Divisão De Farmacêuticos Estabelecido (epd) - São Paulo/sp
jobs.abbott
Sao Paulo, Brazil
Base: not specified; bonus/equity: not specified; ...
Clinical trial methodology across all phases
Biosimilar and branded generic environment experience
Oncology therapeutic area expertise
This position leads the clinical evaluation of new development opportunities for biosimilar oncology products within Abbott's Established Pharmaceuticals Division
Job Summary
This position leads the clinical evaluation of new development opportunities for biosimilar oncology products within Abbott's Established Pharmaceuticals Division.
The role involves designing innovative, risk-based global clinical development programs aligned with business strategy and target product profiles.
Abbott offers a comprehensive benefits package including medical assistance, private pension plans, and flexible work policies to support work-life balance.
Matching Summary
This position leads the clinical evaluation of new development opportunities for biosimilar oncology products within Abbott's Established Pharmaceuticals Division.
Salary
Base: Not specified; Bonus/Equity: Not specified; Benefits: Medical, Dental, Life Insurance, Private Pension Plan, Stock Purchase Discount
Skills & Requirements
Must-have
Clinical trial methodology across all phases
Biosimilar and Branded Generic environment experience
Oncology therapeutic area expertise
Regulatory dossier preparation and submission
Cross-functional team management in global matrix
Nice-to-have
Experience in emerging markets like LATAM and APAC
Digital innovation ideas for disease management
Strong network of Key Opinion Leaders
Fluency in English, Spanish, and Portuguese
Experience with post-marketing study design
Key Requirements
Degree in life sciences or Medical Doctor
Minimum 5 years pharmaceutical industry experience
1-2 years specific Biosimilar-Oncology experience
Minimum 3 years Clinical Development experience
Expert knowledge of Phase 1 through Phase 4 studies